Recent Updates
Recently added Catalysts

Investigational medical product administered in parent study

Phase 3

Osteoarthritis | Small molecule | Musculoskeletal |Pfizer, Inc.|Last Updated: Jun 25, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials2
Total Enrollment158

FDA Designations

No designations recorded

Clinical trial landscape

Investigational medical product administered in parent study · 2 trials · 3 indications

Phase 3 2
NCT03031938Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical StudiesOsteoarthritis
COMPLETED4 Analytics
NCT02674386Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder ReplacementOsteoarthritis
COMPLETED154 Analytics
PHASE3COMPLETED
Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies
OsteoarthritisUnlock trial analytics
PHASE3COMPLETED
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
OsteoarthritisUnlock trial analytics

Study Endpoints

Primary Endpoints

Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Occipital-frontal Head Circumference at 8 Months of Participant's Age
At 8 Months of participants' age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Occipital-frontal Head Circumference at 15 Months of Participant's Age
At 15 Months of participants' age

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Occipital-frontal Head Circumference During 0 to Less Than or Equal to (<=) 3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Occipital-frontal head circumference of participants in centimeter (cm) was reported.

Occipital-frontal Head Circumference During Greater Than (>) 3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Occipital-frontal head circumference of participants in cm was reported.

Occipital-frontal Head Circumference During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Occipital-frontal head circumference of participants in cm was reported.

Occipital-frontal Head Circumference During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Occipital-frontal head circumference of participants in cm was reported.

Occipital-frontal Head Circumference During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Occipital-frontal head circumference of participants in cm was reported.

Occipital-frontal Head Circumference During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Occipital-frontal head circumference of participants in cm was reported.

Body Length During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Body length of participants in cm was reported.

Body Length at 8 Months of Participant's Age
At 8 Months of participant's age

Body length of participants in cm was reported.

Body Length at 15 Months of Participant's Age
At 15 Months of participant's age

Body length of participants in cm was reported.

Body Length During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Body length of participants in cm was reported.

Body Length During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Body length of participants in cm was reported.

Body Length During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Body length of participants in cm was reported.

Body Length During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Body length of participants in cm was reported.

Body Length During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Body length of participants in cm was reported.

Body Length During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Body length of participants in cm was reported.

Body Weight During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Body weight of participants in kilogram (kg) was reported.

Body Weight at 8 Months of Participant's Age
At 8 Months of participants' age

Body weight of participants in kilogram (kg) was reported.

Body Weight at 15 Months of Participant's Age
At 15 Months of participants' age

Body weight of participants in kilogram (kg) was reported.

Body Weight During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Body weight of participants in kilogram (kg) was reported.

Body Weight During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Body weight of participants in kg was reported.

Body Weight During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Body weight of participants in kg was reported.

Body Weight During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Body weight of participants in kg was reported.

Body Weight During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Body weight of participants in kg was reported.

Body Weight During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months up to 30 Months

Body weight of participants in kg was reported.

Systolic and Diastolic Blood Pressure During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Systolic and Diastolic Blood Pressure at 8 Months of Participant's Age
At 8 Months of participants' age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Systolic and Diastolic Blood Pressure at 15 Months of Participant's Age
At 15 Months participants' age

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Systolic and Diastolic Blood Pressure During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Systolic and diastolic blood pressure of participants in millimeter of mercury (mmHg) was reported.

Systolic and Diastolic Blood Pressure During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Systolic and diastolic blood pressure of participants in mmHg was reported.

Systolic and Diastolic Blood Pressure During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Systolic and diastolic blood pressure of participants in mmHg was reported.

Systolic and Diastolic Blood Pressure During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Systolic and diastolic blood pressure of participants in mmHg was reported.

Systolic and Diastolic Blood Pressure During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Systolic and diastolic blood pressure of participants in mmHg was reported.

Systolic and Diastolic Blood Pressure During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Systolic and diastolic blood pressure of participants in mmHg was reported.

Pulse Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate at 8 Months of Participant's Age
At 8 Months of participants' age

Pulse rate of participants in beats per minute was reported.

Pulse Rate at 15 Months of Participant's Age
At 15 Months of participants' age

Pulse rate of participants in beats per minute was reported.

Pulse Rate During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Pulse rate of participants in beats per minute was reported.

Pulse Rate During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Pulse rate of participants in beats per minute was reported.

Temperature During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Temperature of participants in degree Celsius was reported.

Temperature at 8 Months of Participant's Age
At 8 Months of participants' age

Temperature of participants in degree Celsius was reported.

Temperature at 15 Months of Participant's Age
At 15 Months of participants' age

Temperature of participants in degree Celsius was reported.

Temperature During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Temperature of participants in degree Celsius was reported.

Temperature During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Temperature of participants in degree Celsius was reported.

Temperature During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Temperature of participants in degree Celsius was reported.

Temperature During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Temperature of participants in degree Celsius was reported.

Temperature During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Temperature of participants in degree Celsius was reported.

Temperature During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Temperature of participants in degree Celsius was reported.

Respiratory Rate During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate at 8 Months of Participant's Age
At 8 Months of participants' age

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate at 15 Months of Participant's Age
At 15 Months participants' age

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During 0 to <=3 Months of Participant's Age
Any visit during participants' age from 0 to 3 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During >3 to <=6 Months of Participant's Age
Any visit during participants' age above 3 Months and up to 6 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During >6 to <=9 Months of Participant's Age
Any visit during participants' age above 6 Months and up to 9 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During >15 to <=18 Months of Participant's Age
Any visit during participants' age above 15 Months and up to 18 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During >21 to <=24 Months of Participant's Age
Any visit during participants' age above 21 Months and up to 24 Months

Respiratory rate of participants in breaths per minute was reported.

Respiratory Rate During >24 to <=30 Months of Participant's Age
Any visit during participants' age above 24 Months and up to 30 Months

Respiratory rate of participants in breaths per minute was reported.

Number of Participants With Abnormal Neurological Examination Findings During 0 to Less Than or Equal to (<=) 2 Months of Participant's Age
Any visit during participants' age from 0 to 2 Months

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Number of Participants With Abnormal Neurological Examination Findings at 8 Months of Participant's Age
At 8 Months of participants' age

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Number of Participants With Abnormal Neurological Examination Findings at 15 Months of Participant's Age
At 15 Months of participants' age

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 1 (Month 20 of Participant's Age)
Follow-up Visit 1 (At the age of Month 20)

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Number of Participants With Abnormal Neurological Examination Findings at Follow-up Visit 2 (Month 26 of Participant's Age)
Follow-up Visit 2 (At the age of 26 Months)

Neurologic examination evaluated all cranial nerves except I (smell), IX (taste) and XI (shoulder shrug). Motor examination included evaluation of muscle tone, bulk and movement. Sensory examination included test of temperature and superficial pain (homologous dermatomes using cold tuning fork, neurological examination pin) and deep pain by pressure on achilles tendon. Reflex evaluation included biceps, brachioradialis, patellar, and achilles tendons. Evaluation for persistence of developmental reflexes including Moro reflex, palmar and planter grasp, and tonic neck response was evaluated. Autonomic nervous system evaluation included examination of pupillary reaction, heart rate changes in response to activity, and inquiring about abnormal sweating. Abnormality was determined by the assessor.

Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 8 of Participant's Age
At 8 Months of participants' age

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Month 15 of Participant's Age
At 15 Months of participants' age

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 1 (Month 20 of Participant's Age)
Follow-up Visit 1 (At the age of Month 20)

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance.

Bayley Infant Neurodevelopmental Screener (BINS) Total Score at Follow-up Visit 2 (Month 26 of Participant's Age)
Follow-up Visit 2 (At the age of Month 26)

BINS: a validated instrument designed specifically for a high-risk infant population. It consisted of 11-13 items for different age levels (11 items for participants aged from 3-4 months, 11-15 months, 16-20 months; 13 items for participants aged from 5-6 months, 7-10 months, 21-24 months) to assess cognitive, social, language, gross, and fine motor skills. Each item was scored on a range 0 = non-optimal performance to 1 = optimal performance; BINS total score was sum of scores of each item and it ranged for 11 items from 0 (non-optimal performance) to 11 (optimum performance) and for 13 items from 0 (non-optimal performance) to 13 (optimum performance), higher score indicated better performance. Data collected at age of 26 months used 24 months' age items.

Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 8 of Participant's Age
At 8 Months of participants' age

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Month 15 of Participant's Age
At 15 Months of participants' age

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 1 (Month 20 of Participant's Age)
Follow-up Visit 1 (At the age of Month 20)

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Bzoch-League Receptive Expressive Emergent Language Test 3rd Edition (REEL-3) Language Ability Score at Follow-up Visit 2 (Month 26 of Participant's Age)
Follow-up Visit 2 (At the age of Month 26)

REEL-3, was designed to identify infants and toddlers who had language impairments or who had other disabilities that affect language development. Caregiver answered interview questionnaire by pediatrician, pediatric neurologist or clinical psychologist for receptive language and expressive language subtests. Each of these 2 sub tests had 66 questions with answer of 'yes = 1' or 'no = 0'. Sum of receptive and expressive language subtests answers was used to calculate REEL-3 language ability total score, with following ranges: \<70 (very poor), 70-79 (poor), 80-89 (below average), 90-110 (average), 111-120 (above average), 121-130 (superior), and \>130 (very superior). Higher scores indicated better language ability.

Number of Participants With Surgeon's Assessment of Procedural Difficulty
Day 1

Following the TJR surgery on Day 1, the orthopedic surgeon was asked to answer the following question: "taking into consideration the participant's medical history and physical condition prior to surgery would you classify the operative procedure as Uneventful, Minor complications or Major complications." Participants were reported based on these categories for knee, hip and shoulder joint. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Number of Participants With Overall Satisfaction With Surgery as Assessed by the Self-Administered Patient Satisfaction (SAPS) Scale at Week 24
Week 24

SAPS contained four questions; How satisfied are you with the 1) results of your surgery 2) results of surgery for improving pain 3) results of surgery for improving ability to do home or yard work, and 4) results of surgery for improving your ability to do recreational activities. Items scored on a 4-point Likert scale with response of 'very satisfied' (100 points), 'somewhat satisfied' (75 points), 'somewhat dissatisfied' (50 points), and 'very dissatisfied' (25 points). The scale score calculated as mean of the scores of individual items, ranging from 25 to 100, with higher scores indicating greater satisfaction. Here, number of participants are summarized as, satisfied (very satisfied and somewhat satisfied categories combined) and dissatisfied (somewhat dissatisfied and very dissatisfied categories combined). Participants may have been counted more than once if they had TJR surgery in more than one joint.

Number of Participants With Post-Surgical Complications Upto Week 24
Baseline up to Week 24

Post-surgical complications are adverse events occurring after TJR surgery that were considered clinically significant as assessed by investigator and attributable to the total joint replacement procedure. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Number of Participants With Additional or Corrective Procedures Related to Total Joint Replacement Upto Week 24
Baseline up to Week 24

Participants were asked whether they had been told by their orthopedic surgeon that additional or corrective procedures were necessary for their total joint replacement. Participants, who responded as yes have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Number of Participants Who Participated in Physical Rehabilitation Activities Related to Total Joint Replacement Upto Week 24
Baseline up to Week 24

Participants responded with a yes or no to the following question ''are you participating in physical rehabilitation activities related to your replaced joint''. Participants responded with a yes, have been reported here. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Change From Baseline in Average Pain Score in to be Replaced or Replaced Joints at Week 24
Baseline, Week 24

Participants assessed their average pain in to be replaced (pre-surgery) knee/ hip joint or in the replaced joint (post-surgery) in the past 24 hours using an 11-point numerical rating scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24
Baseline, Week 24

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of to be replaced/replaced index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 24
Baseline, Week 24

WOMAC: self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the replaced/to be replaced index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness. Change from baseline was calculated using the difference between post-baseline weekly mean and the baseline mean score. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24
Baseline, Week 24

WOMAC: Self-administered, disease-specific questionnaire, which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in replaced/ to be replaced index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions, which may not be a whole (integer) number, scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Participants may have been counted more than once if they had TJR surgery in more than one joint.

Change From Baseline in Shoulder Pain and Disability Index (SPADI) Score at Week 24
Baseline, Week 24

SPADI: self-administered questionnaire to measure pain and disability associated with shoulder pathology in participants with shoulder pain. It consists of two dimensions pain and function. Pain dimension:5 questions regarding severity of pain, scores ranged from 0=no pain to 10=worst pain imaginable, higher scores indicated extreme pain. Functional activities:8 questions to measure degree of difficulty with various activities of daily living that require upper extremity use, scores ranged from 0=no difficulty to 10=so difficult it requires help, higher scores=extreme difficulty. Pain and disability dimension score was calculated as the sum of non-missing scores divided by the maximum possible score (50 \[for pain\] and 80 \[for disability\]) multiplied by 100. A total score was calculated as the mean of two dimensions, ranged from 0=best to 100=worst, higher scores indicated worsening of condition.

Number of Participants Who Used Concomitant Analgesic Medications
Baseline up to Week 24
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeOTHER

Treatment Arms

ArmTypeDescription
Cohort 1OTHERLong term observational study of subjects from tanezumab parent study

Interventions

NameTypeDescription
Investigational medical product (IMP) administered in parent studyDRUGIMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
Unlock Study Design Details

Eligibility Criteria

Age Range0 Years to 2 Months
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical study. * The infant's mother (who was the tanezumab clinical study participant) must review, agree and sign an informed consent document explaining the details of the perinatal and post...

Countries:United StatesAustraliaCanadaGermanyHungaryItalyJapanLithuaniaNew ZealandPortugalRussiaSerbiaSlovakiaSpainSweden
Unlock Eligibility Criteria